Kirby Institute

This pilot study is testing whether a 4-week course of two antiviral drugs—sofosbuvir plus glecaprevir/pibrentasvir—can cure chronic hepatitis C in people who have not been treated before and have only mild liver scarring. Participants who relapse after the short treatment will r…

This project aims to make hepatitis C testing and treatment easier for people who visit drug treatment clinics and needle exchange programs. Researchers will work with clinics across New South Wales, Australia, to help more people start treatment. The study includes up to 6,000 a…

This study compares two drugs, ivermectin and moxidectin, to see which works better at controlling river blindness and other common infections like intestinal worms and scabies in Angola. Over 52,000 people in 20 village groups will receive one of the drugs once a year for four y…

This large Australian study is testing whether offering a finger-stick point-of-care test for hepatitis C can increase diagnosis and treatment rates. Adults at risk for hepatitis C will be offered the rapid test at services they already use. Those who test positive for the virus …

This large Australian study is testing whether offering finger-stick point-of-care testing for hepatitis C in community settings—like drug treatment clinics, homeless shelters, and prisons—can increase the number of people diagnosed and linked to treatment. The study will include…

This study is testing whether a quick finger-stick test can help find more people with hepatitis C and get them into treatment. About 60,000 adults at risk for hepatitis C will take the test at clinics, shelters, or prisons. The study itself does not provide treatment, but will c…

This study will follow 10,000 people in Australia who have chronic hepatitis B to see how well they are connected to care and treatment. Researchers will collect information from clinics across the country to understand who is getting treated and what their health needs are. No n…

This study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…